NCT02381821

Brief Summary

100 patients aged 21-40 years old, diagnosed as primary or secondary infertility These patients are then assigned to receive ICSI treatment (ovulation induction, . They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation. Intervention(s) All patients will undergo 3D ultrasound to measure the thickness of the junctional zone at day 21 of the cycle.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
82

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2016

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 3, 2015

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 6, 2015

Completed
10 months until next milestone

Study Start

First participant enrolled

January 1, 2016

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 3, 2017

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2017

Completed
Last Updated

January 3, 2018

Status Verified

January 1, 2018

Enrollment Period

1.9 years

First QC Date

March 3, 2015

Last Update Submit

January 2, 2018

Conditions

Keywords

junctional zoneImplantationIntracytoplasmic sperm injection

Outcome Measures

Primary Outcomes (1)

  • pregnancy rate

    14 days after embryo transfer

Study Arms (2)

pregnant

women undergoing ICSI who became pregnant

Other: 3 D ultrasound and Doppler examinationDrug: GnRH agonist

Not pregnant

women undergoing ICSI who fail to achieve pregnancy

Other: 3 D ultrasound and Doppler examinationDrug: GnRH agonist

Interventions

Endometrial thickness was measured in the longitudinal plane at the widest anteroposterior diameter with a trans-vaginal 2D ultrasound, and then 3D mode was then activated with power Doppler setting for this study standardized using a frequency at 4-9 MHZ pulse repetition frequency at 0.5KHz gain at-3.0 and wall motion filter at 1. The sub-endometrial region was considered to be within 3 mm of the originally defined myometrial-endometrial contour. The endometrial volume (EV) and 3D power Doppler indices below the endometrium were measured using the automated VOCAL™ for the 3D power Doppler histogram analysis

Not pregnantpregnant

All women received daily subcutaneous 0.1 mg triptorelin injection started from day 21) of the cycle preceding stimulation. Downregulation of the pituitary gonadotropins was confirmed after 12 days , gonadotropin (Gn) induction was started using Human menopausal gonadotropins for ovarian stimulation. The starting dose was 225 to 300 IU . Ultrasound Folliculometry was done every other day . When two or more follicles reached a minimum mean diameter of 18 mm, triggering of ovulation trigger was done using Human chorionic gonadotropin (hCG) 10,000 IU and ovum pick up was scheduled 36 hours later

Not pregnantpregnant

Eligibility Criteria

Age19 Years - 39 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

women with primary or secondary infertility and were scheduled for a first IVF/ICSI treatment cycle due to Pelvic Inflammatory disease, ovulatory dysfunction, tubal infertility, unexplained infertility , combined infertility with normal transvaginal ultrasound.

You may qualify if:

  • A normal transvaginal ultrasound is defined as having no visible intracavitary pathology (e.g. submucous myomas, polyps or septa) and was be performed in the follicular phase of the menstrual cycle. Intramural myomas without impression or deformation of the uterine cavity were incorporated in the definition of a normal ultrasound

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Helping Behavior

Interventions

Gonadotropin-Releasing Hormone

Condition Hierarchy (Ancestors)

Social BehaviorBehavior

Intervention Hierarchy (Ancestors)

Pituitary Hormone-Releasing HormonesHypothalamic HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsNeuropeptidesPeptidesAmino Acids, Peptides, and ProteinsOligopeptidesNerve Tissue ProteinsProteins

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor

Study Record Dates

First Submitted

March 3, 2015

First Posted

March 6, 2015

Study Start

January 1, 2016

Primary Completion

December 3, 2017

Study Completion

December 31, 2017

Last Updated

January 3, 2018

Record last verified: 2018-01